GSK Faces Legal Challenges Over Zantac
Pharmaceutical giant GSK faces significant legal challenges as the Delaware State Court allows expert witnesses to present scientific evidence in lawsuits related to the discontinued heartburn drug, Zantac. This pivotal ruling has led to a notable decline in GSK's stock value, reflecting investor concerns about the potential impact of these lawsuits. The court's decision underscores the importance of scientific evidence in determining the drug's safety and its implications for consumers, potentially influencing the outcome of approximately seventy-five thousand cases. The market's reaction highlights the uncertainty and financial repercussions GSK may encounter, with far-reaching consequences for the company's reputation and stability.